Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia

Druker et al. (Sat,) studied this question.

www.synapsesocial.com/papers/6a088a5b1e8b9db648de1422 — DOI: https://doi.org/10.1172/jci9083

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Crystal Structure of Hck in Complex with a Src Family–Selective Tyrosine Kinase Inhibitor· 1999 · 425 citations
2. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.· 1996 · 1,080 citations
3. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors· 1999 · 255 citations
4. Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia· 1999 · 125 citations
5. The Structure-Based Design of ATP-Site Directed Protein KinaseInhibitors· 1999 · 175 citations